Abstract:Background: Mucous hypersecretion increases asthma morbidity and mortality. Tumor necrosis factor alpha (TNF-alpha) levels are elevated in bronchoalveolar fluid, sputum, and monocyte membranes in some patients with asthma. Anti-TNF-alpha decreased asthma exacerbations and improved forced expiratory volume in I second in these patients. Whether anti-TNF-alpha reduces mucous cell metaplasia or hyperplasia has not been evaluated.Objective: To investigate the role of anti-TNF-alpha in mucous hypersecretion.Methods: BALB/c mice sensitized intraperitoneally and challenged intratracheally with ovalbumin were treated with 250 mu g of anti-TNF-alpha before ovalbumin sensitization and challenge or before only ovalbumin challenge. Control groups were sham treated. The tumor necrosis factor receptor (TNFR) mice (TNFR-/- and TNFR+/+) were identically sensitized and challenged. Seventy-two hours after the final challenge, the airway pressure time index (APTI), which measures airway hyperresponsiveness, was recorded. Mucous cell metaplasia was accessed by quantitative polymerase chain reaction for MUC-5AC (the epithelial cell mucous-inducing gene) and the percentage of periodic acid-Schiff (PAS) staining of bronchial epithelial cells. A human airway cell line (constitutively expressing MUC-5AC) was pretreated with a NF-kappa B inhibitor before TNF-alpha culture.Results: The mean (SE) fold change of MUC-5AC expression (compared with naive controls), the percentage of PAS-positive bronchiole epithelial cells, and the APTI decreased in BALB/c mice treated with anti-TNF-alpha before sensitization and challenge (4.9 [1.14], P = .007; 28.9% [6.8%], P < .001; and 545.8 [104.5] cm H2O/s, P < .001, respectively) and before challenge alone (9.3 [1.8], P = .03; 43.6% [10.7%], P = .009; and 896.8 [81.23] cm H2O/s, P = .06, respectively) compared with sham-treated mice (20.9 [3.9], 82.4% [1.8%], and 1,055 [30.6] cm H2O/s, respectively). MUC-5AC expression decreased in ovalbumin sensitized or challenged TNFR-/- (2.41 [0.4]) compared with ovalbumin sensitized or challenged TNFR+/+ mice (18.4 [2.5], P < .001). TNF-alpha-induced MUC-5AC expression in human airway culture significantly decreased with pretreatment of a NF-kappa B inhibitor.Conclusions: Anti-TNF-alpha treatment reduces airway mucous cell metaplasia in a mouse model of asthma, which may in part underlie its beneficial effect as asthma therapy. Ann Allergy Asthma Immunol. 2009; 103:295-303.

Progress of anti-tumor necrosis factor-α for severe asthma

Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Infliximab Alleviates Inflammation and Ex Vivo Airway Hyperreactivity in Asthmatic E3 Rats.

Recent Advance in Regulatory T Cells and Bronchial Asthma

Adenoviral delivery of recombinant soluble human tumor necrosis factor receptor 1 partially normalized mouse model of asthma.

Relationship between anti-tumor necrosis factor -α monoclonal antibody and chronic colitis in mice.

Antibody therapy for the management of severe asthma with eosinophilic inflammation

Therapeutic Potential of TNFα Inhibitors in Chronic Inflammatory Disorders: Past and Future

New Targeted Therapies for Uncontrolled Asthma

Emerging interleukin receptor antagonists for the treatment of asthma

Novel asthma treatments: Advancing Beyond Approved Novel Step-Up Therapies for Asthma

Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

From Biomarkers to Biologics

The Effects of Tumor Necrosis Factor-α Inhibitor on Airway Inflammation of Emphysema Rat Models

Tannic Acid Assisted Anti-Tnf-α Nanobody Assembly Modulating the Epithelial Barrier Dysregulation of Allergic Rhinitis

Decrease in Airway Mucous Gene Expression Caused by Treatment with Anti-Tumor Necrosis Factor Alpha in A Murine Model of Allergic Asthma

Progress of Tumor Necrosis Factor Alpha Inhibitors in Treatment of Rheumatoid Arthritis

[New Therapeutic Targets and Drugs for the Severe Asthma]

Biologics or immunotherapeutics for asthma?

Promises and challenges of biologics for severe asthma

Biologic therapies for severe asthma with persistent type 2 inflammation